Report of Foreign Issuer (6-k)

 

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

 

For the month of		February		2018
Commission File Number		001-36458

 

Neovasc Inc.

(Translation of registrant’s name into English)

Suite 5138 – 13562 Maycrest Way Richmond, British Columbia, Canada V6V 2J7

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

Form 40-F

X

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):           

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):           

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

 

Document
1		News Release dated February 12, 2018 - Neovasc to Present at LEERINK Partners 7th Annual Global Healthcare Conference

 

 

 

Document 1

 

Neovasc to Present at LEERINK Partners 7th Annual Global Healthcare Conference

NASDAQ, TSX: NVCN

VANCOUVER, Feb. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the LEERINK Partners 7 ^th Annual Global Healthcare Conference on Wednesday, February 14 ^th  at 2:30 pm ET at the Lotte New York Palace in New York City.

A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe.  For more information, visit: www.neovasc.com.

SOURCE Neovasc Inc.

 

View original content: http://www.newswire.ca/en/releases/archive/February2018/12/c4196.html

%CIK: 0001399708

For further information: Investor Relations: Neovasc Inc., Chris Clark, 604 248-4138, [e-mail]

CO: Neovasc Inc.

CNW 07:00e 12-FEB-18

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Neovasc Inc.
	(Registrant)
Date:           February 12, 2018	By:	/s/ Chris Clark
		Name:	Chris Clark
		Title:	Chief Financial Officer